Patents by Inventor Daniel FINAN
Daniel FINAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11497851Abstract: A system and a method for management of diabetes are provided. The system includes an infusion pump, glucose sensor, and controller that is programmed to control insulin delivery based upon at least one stored variable. The controller calculates a maximum insulin delivery rate based on the default basal insulin delivery rate, temporary basal insulin delivery rate, extended bolus rate, or a combination thereof.Type: GrantFiled: March 31, 2017Date of Patent: November 15, 2022Assignee: Lifescan IP Holdings, LLCInventors: Daniel Finan, Pavel Vereshchetin
-
Publication number: 20220031950Abstract: Systems and methods for diabetes management with automatic basal and manual bolus insulin control are presented. An exemplary system includes a delivery device, a glucose sensor, and a controller. The delivery device delivers insulin and the glucose sensor measures glucose levels of the subject. A basal insulin dose is calculated using a model predictive control algorithm and physiological data of the subject including desired glucose levels, amounts of the delivered insulin and the measured glucose levels. A manual bolus insulin dose is initiated by the subject. The manual bolus insulin dose is modified based on one or both of the model predictive control algorithm and the physiological data of the subject. A total insulin dose is determined based on the modified manual bolus insulin dose and the calculated basal insulin dose, and delivered to the subject.Type: ApplicationFiled: October 18, 2021Publication date: February 3, 2022Inventors: Daniel Finan, Thomas McCann
-
Patent number: 11147920Abstract: Systems and methods for diabetes management with automatic basal and manual bolus insulin control are presented. An exemplary system includes a delivery device, a glucose sensor, and a controller. The delivery device delivers insulin and the glucose sensor measures glucose levels of the subject. A basal insulin dose is calculated using a model predictive control algorithm and physiological data of the subject including desired glucose levels, amounts of the delivered insulin and the measured glucose levels. A manual bolus insulin dose is initiated by the subject. The manual bolus insulin dose is modified based on one or both of the model predictive control algorithm and the physiological data of the subject. A total insulin dose is determined based on the modified manual bolus insulin dose and the calculated basal insulin dose, and delivered to the subject.Type: GrantFiled: April 18, 2017Date of Patent: October 19, 2021Assignee: LifeScan IP Holdings, LLCInventors: Daniel Finan, Thomas McCann, Jr.
-
Patent number: 10729849Abstract: An artificial pancreas system includes a continuous glucose monitoring device, a drug delivery device configured to exchange data with the continuous glucose monitoring device and containing a control algorithm, and possibly a remote controller configured to exchange data with the drug delivery device. The algorithm contains an insulin-glucose model, but is decoupled mathematically from the insulin injected by the user to offset the ingested carbohydrates. The control algorithm is designed to calculate two versions of insulin-on-board-patient-facing insulin-on-board (PFIOB) and system-facing insulin-on-board (SFIOB) to properly parse boluses and inform the system of only the insulin that is intended for high glucose correction, but not carbohydrate offsetting.Type: GrantFiled: April 7, 2017Date of Patent: August 4, 2020Assignee: LifeSpan IP Holdings, LLCInventors: Daniel Finan, Pavel Vereshchetin
-
Patent number: 10583249Abstract: A visualization and analysis tool is provided for an insulin delivery system, such as an artificial pancreas, in which insulin is delivered based upon a system algorithm using a pump that is patient controllable in order to adjust insulin delivery relative to a baseline delivery rate; e.g., pre-set basal rate and a sensor for measuring glucose levels. The tool is configured with a controller of the system to detect and log events that are based on differences between actual insulin delivered by the system and the baseline delivery rate. These detected events are metrics that provide information relating to the therapeutic value of the system which, without such metrics, may be overlooked or unnoticed, thereby fostering trust and confidence in the delivery system. In addition, information is provided which may enable further improved glucose control.Type: GrantFiled: January 20, 2017Date of Patent: March 10, 2020Assignee: LifeScan IP Holdings, LLCInventors: Daniel Finan, Pavel Vereshchetin
-
Publication number: 20180296757Abstract: Systems and methods for diabetes management with automatic basal and manual bolus insulin control are presented. An exemplary system includes a delivery device, a glucose sensor, and a controller. The delivery device delivers insulin and the glucose sensor measures glucose levels of the subject. A basal insulin dose is calculated using a model predictive control algorithm and physiological data of the subject including desired glucose levels, amounts of the delivered insulin and the measured glucose levels. A manual bolus insulin dose is initiated by the subject. The manual bolus insulin dose is modified based on one or both of the model predictive control algorithm and the physiological data of the subject. A total insulin dose is determined based on the modified manual bolus insulin dose and the calculated basal insulin dose, and delivered to the subject.Type: ApplicationFiled: April 18, 2017Publication date: October 18, 2018Inventors: Daniel FINAN, Thomas MCCANN, JR.
-
Publication number: 20180289891Abstract: An artificial pancreas system includes a continuous glucose monitoring device, a drug delivery device configured to exchange data with the continuous glucose monitoring device and containing a control algorithm, and possibly a remote controller configured to exchange data with the drug delivery device. The algorithm contains an insulin-glucose model, but is decoupled mathematically from the insulin injected by the user to offset the ingested carbohydrates. The control algorithm is designed to calculate two versions of insulin-on-board-patient-facing insulin-on-board (PFIOB) and system-facing insulin-on-board (SFIOB) to properly parse boluses and inform the system of only the insulin that is intended for high glucose correction, but not carbohydrate offsetting.Type: ApplicationFiled: April 7, 2017Publication date: October 11, 2018Inventors: Daniel FINAN, Pavel VERESHCHETIN
-
Publication number: 20180280619Abstract: A system and a method for management of diabetes are provided. The system includes an infusion pump, glucose sensor, and controller that is programmed to control insulin delivery based upon at least one stored variable. The controller calculates a maximum insulin delivery rate based on the default basal insulin delivery rate, temporary basal insulin delivery rate, extended bolus rate, or a combination thereof.Type: ApplicationFiled: March 31, 2017Publication date: October 4, 2018Inventors: Daniel FINAN, Pavel VERESHCHETIN
-
Publication number: 20180147348Abstract: The invention provides for disabling of the audio bolus feature of a drug delivery system on the occurrence, or predicted occurrence, of certain events mitigating the problem of a user delivering unneeded drug. The invention provides a drug delivery system having at least one controller configured to autonomously modulate drug delivery from the drug delivery device, a sensor for measuring an analyte of the user, and an audio bolus feature, wherein the audio bolus feature is automatically disabled if the controller determines a therapeutically significant state is present.Type: ApplicationFiled: November 27, 2017Publication date: May 31, 2018Inventors: Thomas MCCANN, Daniel FINAN, Anthony DIUBALDI, Brian LEVY
-
Publication number: 20180147349Abstract: Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed into the controller. The infusion pump is configured to deliver insulin to a subject. The glucose sensor is configured to sense glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed to switchover from one mode of MPC control based on a predetermined range of blood glucose values to another MPC mode based on a predetermined target.Type: ApplicationFiled: January 29, 2018Publication date: May 31, 2018Inventors: Daniel FINAN, Thomas MCCANN
-
Patent number: 9907909Abstract: Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed into the controller. The infusion pump is configured to deliver insulin to a subject. The glucose sensor is configured to sense glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed to switchover from one mode of MPC control based on a predetermined range of blood glucose values to another MPC mode based on a predetermined target.Type: GrantFiled: December 20, 2012Date of Patent: March 6, 2018Assignee: Animas CorporationInventors: Daniel Finan, Thomas McCann
-
Publication number: 20180043095Abstract: Methods and systems for controlling an insulin pump in response to glucose measurements are responsive to a base insulin delivery profile and a temporary insulin delivery profile. These can be used, e.g., to control blood glucose level of a subject using a continuous glucose monitor and an insulin infusion pump. During a selected time range, an insulin amount for the pump to supply is determined using the temporary insulin delivery profile. Outside that time range, the insulin amount is determined using the base insulin delivery profile. The temporary insulin delivery profile can specify an exact amount to be supplied (a “hard” profile), a nominal amount to be supplied if doing so does not drive glucose out of a desired zone (“soft”), or a soft profile with a minimum amount of insulin to be delivered (“semi-soft”).Type: ApplicationFiled: October 3, 2017Publication date: February 15, 2018Inventors: Daniel FINAN, Thomas MCCANN
-
Patent number: 9795737Abstract: Methods and systems for controlling an insulin pump in response to glucose measurements are responsive to a base insulin delivery profile and a temporary insulin delivery profile. These can be used, e.g., to control blood glucose level of a subject using a continuous glucose monitor and an insulin infusion pump. During a selected time range, an insulin amount for the pump to supply is determined using the temporary insulin delivery profile. Outside that time range, the insulin amount is determined using the base insulin delivery profile. The temporary insulin delivery profile can specify an exact amount to be supplied (a “hard” profile), a nominal amount to be supplied if doing so does not drive glucose out of a desired zone (“soft”), or a soft profile with a minimum amount of insulin to be delivered (“semi-soft”).Type: GrantFiled: March 15, 2013Date of Patent: October 24, 2017Assignee: ANIMAS CORPORATIONInventors: Daniel Finan, Thomas McCann
-
Patent number: 9757510Abstract: Described and illustrated is a diabetes management system that includes an infusion pump, glucose sensor and controller with a method programmed into the controller. The infusion pump is configured to deliver insulin to a subject. The glucose sensor is configured to sense glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed to receive signals from at least one of the glucose sensor and the pump and configured to issue signals to the pump to deliver an amount of insulin determined by a feedback controller that utilizes a model predictive control and also configured to deliver at least the basal amount of insulin whenever the subject has initiated a manual bolus of insulin and a sensed or measured glucose level is at least a first threshold within a first duration of time.Type: GrantFiled: June 29, 2012Date of Patent: September 12, 2017Assignee: Animas CorporationInventor: Daniel Finan
-
Publication number: 20170224920Abstract: A visualization and analysis tool is provided for an insulin delivery system, such as an artificial pancreas, in which insulin is delivered based upon a system algorithm using a pump that is patient controllable in order to adjust insulin delivery relative to a baseline delivery rate; e.g., pre-set basal rate and a sensor for measuring glucose levels. The tool is configured with a controller of the system to detect and log events that are based on differences between actual insulin delivered by the system and the baseline delivery rate. These detected events are metrics that provide information relating to the therapeutic value of the system which, without such metrics, may be overlooked or unnoticed, thereby fostering trust and confidence in the delivery system. In addition, information is provided which may enable further improved glucose control.Type: ApplicationFiled: January 20, 2017Publication date: August 10, 2017Inventors: Daniel FINAN, Pavel VERESHCHETIN
-
Patent number: 9486578Abstract: Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed into the controller. The infusion pump is configured to deliver insulin to a subject. The glucose sensor is configured to sense glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed receives signals from at least one of the glucose sensor and the pump and configured to issue signals to the pump to deliver an amount of insulin determined by a feedback controller that utilizes a model predictive control of the subject based on desired glucose levels, insulin amount delivered and measured glucose levels of the subject. The controller is also configured to deliver insulin using a tuning factor based on either one of an omission index module or a calibration index module.Type: GrantFiled: December 7, 2012Date of Patent: November 8, 2016Assignee: Animas CorporationInventors: Daniel Finan, Thomas McCann, Ramakrishna Venugopalan
-
Publication number: 20140276554Abstract: Methods and systems for controlling an insulin pump in response to glucose measurements are responsive to a base insulin delivery profile and a temporary insulin delivery profile. These can be used, e.g., to control blood glucose level of a subject using a continuous glucose monitor and an insulin infusion pump. During a selected time range, an insulin amount for the pump to supply is determined using the temporary insulin delivery profile. Outside that time range, the insulin amount is determined using the base insulin delivery profile. The temporary insulin delivery profile can specify an exact amount to be supplied (a “hard” profile), a nominal amount to be supplied if doing so does not drive glucose out of a desired zone (“soft”), or a soft profile with a minimum amount of insulin to be delivered (“semi-soft”).Type: ApplicationFiled: March 15, 2013Publication date: September 18, 2014Inventors: Daniel Finan, Thomas McCann
-
Publication number: 20140180240Abstract: Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed into the controller. The infusion pump is configured to deliver insulin to a subject. The glucose sensor is configured to sense glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed to switchover from one mode of MPC control based on a predetermined range of blood glucose values to another MPC mode based on a predetermined target.Type: ApplicationFiled: December 20, 2012Publication date: June 26, 2014Applicant: Animas CorporationInventors: Daniel FINAN, Thomas McCANN
-
Publication number: 20140163517Abstract: Described and illustrated is a system for management of diabetes that includes an infusion pump, glucose sensor and controller with a method programmed into the controller. The infusion pump is configured to deliver insulin to a subject. The glucose sensor is configured to sense glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed receives signals from at least one of the glucose sensor and the pump and configured to issue signals to the pump to deliver an amount of insulin determined by a feedback controller that utilizes a model predictive control of the subject based on desired glucose levels, insulin amount delivered and measured glucose levels of the subject. The controller is also configured to deliver insulin using a tuning factor based on either one of an omission index module or a calibration index module.Type: ApplicationFiled: December 7, 2012Publication date: June 12, 2014Applicant: Animas CorporationInventors: Daniel FINAN, Thomas McCANN, Ramakrishna Venugopalan
-
Publication number: 20140005633Abstract: Described and illustrated is a diabetes management system that includes an infusion pump, glucose sensor and controller with a method programmed into the controller. The infusion pump is configured to deliver insulin to a subject. The glucose sensor is configured to sense glucose levels in the subject and provide output signals representative of the glucose levels in the subject. The controller is programmed to receive signals from at least one of the glucose sensor and the pump and configured to issue signals to the pump to deliver an amount of insulin determined by a feedback controller that utilizes a model predictive control and also configured to deliver at least the basal amount of insulin whenever the subject has initiated a manual bolus of insulin and a sensed or measured glucose level is at least a first threshold within a first duration of time.Type: ApplicationFiled: June 29, 2012Publication date: January 2, 2014Applicant: Animas CorporationInventor: Daniel FINAN